drugset / Trial / NCT06187402
A Study of LM-24C5 For Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors.
Timeline
- Start
- 2023-12-20
- Primary completion
- 2026-06-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LM-24C5 | Unknown | — | Intravenous |